



Curriculum Vitae

Personal information **Ingvild Løberg Tangen**

Work experience

Nov 2018 - senior advisor, Norwegian medicinal product agency
Jan 2017 - Oct 2018, Postdoctoral researcher, Helse Vest
July 2016-Dec 2016 Researcher, Helse Vest
Nov 2011 - June 2016 PhD student University of Bergen
Dec 2010 - Oct 2011, Pharmacist, Vitusapotek Hitra
Nov 2008 - Nov 2010, Regulatory Affairs Associate, Novartis Norge AS
Oct 2006 - Oct 2008, Regulatory Affairs Associate, Smerud Medical Research
Dec 2005 - Sep 2006, Pharmacist, Nesbru Pharmacy

Education and training

Aug 2000 - Nov 2005, Msc. Pharm, University of Oslo, Norway

Nov 2011 - June 2016, PhD, University of Bergen, Norway

Additional information

Publications

Nuclear upregulation of class I phosphoinositide 3-kinase p110 β correlates with high 47S rRNA levels in cancer cells. Nuclear upregulation of class I phosphoinositide 3-kinase p110 β correlates with high 47S rRNA levels in cancer cells. *J Cell Sci.* · 10. feb. 2021

Blood Metabolites Associate with Prognosis in Endometrial Cancer. Blood Metabolites Associate with Prognosis in Endometrial Cancer. *Metabolites* · 14. des. 2019

Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling. *Gynecol Oncol* · 6. des. 2019

Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study. Impact of body mass index and fat distribution on sex steroid levels in endometrial carcinoma: a retrospective study. *BMC Cancer* · 7. jun. 2019

Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. *Hum Pathol* · 3. mai 2019

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. *PLoS One.* · 15. jan. 2019

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. *PLoS One.* · 1. nov. 2018

Blood steroids are associated with prognosis and fat distribution in endometrial cancer. Blood steroids are associated with prognosis and fat distribution in endometrial cancer. *Gynecol Oncol.* · 26. okt. 2018

Ovarian Cancer Association Consortium. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. Ovarian Cancer Association Consortium. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *Int J Mol Sci.* · 21. aug. 2018

Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. *BJOG* · 19. aug. 2018

Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS One.* · 6. jul. 2018

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. *Br J Cancer.* · 23. nov. 2017

Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. *Acta Radiol.* · 14. nov. 2017

Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently

lost in metastatic lesions. Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. *Gynecol Oncol.* · 31. okt. 2017

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. *Oncotarget* · 31. okt. 2017

High visceral fat percentage is associated with poor outcome in endometrial cancer. High visceral fat percentage is associated with poor outcome in endometrial cancer. *Oncotarget* · 19. okt. 2017

Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. *Gynecol Oncol.* · 18. sep. 2017

Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. *Br J Cancer.* · 5. sep. 2017

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. *Sci Rep* · 31. aug. 2017

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. *Oncotarget* · 31. jul. 2017

Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. *Am J Obstet Gynecol.* · 24. jun. 2017

Endometrial cancer cells exhibit high expression of p110 β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Endometrial cancer cells exhibit high expression of p110 β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. *Oncotarget* · 17. jan. 2017

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget* · 25. okt. 2016

Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. *Oncotarget* · 25. okt. 2016

Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. *Oncotarget* · 2. aug. 2016

Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. *Carcinogenesis* · 29. sep. 2015

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. *Oncotarget* · 29. sep. 2015

Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. *Nat Commun.* · 22. sep. 2015

Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *J Genet Genome Res.* · 15. sep. 2015

Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Hum Mol Genet.* · 1. jul. 2015

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS One.* · 29. jun. 2015

Genome-wide significant risk associations for mucinous ovarian carcinoma. Genome-wide significant risk associations for mucinous ovarian carcinoma. *Nat Genet.* · 15. jun. 2015

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol.* · 2. mai 2015

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. *Oncotarget* · 20. jan. 2015

Consortium of Investigators of Modifiers of BRCA1 and BRCA2. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Consortium of Investigators of Modifiers of BRCA1 and BRCA2. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet.* · 12. jan. 2015

Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecol Oncol.* · 17. des. 2014

Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. *Cancer Epidemiol Biomarkers Prev.* · 24. okt. 2014

Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. *Eur J Cancer* · 30. sep. 2014

Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genet Epidemiol.* · 24. sep. 2014

Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with

ovarian carcinoma risk. Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Mol Nutr Food Res · 28. jul. 2014

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. Br J Cancer · 8. jul. 2014

Switch in FOXA1 status associates with endometrial cancer progression. Switch in FOXA1 status associates with endometrial cancer progression. PLoS One · 21. mai 2014

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer PLoS One · 25. feb. 2014

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)